- Home
- KALV
as of 02-26-2026 9:35am EST
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | FRAMINGHAM |
| Market Cap: | 757.7M | IPO Year: | 2014 |
| Target Price: | $30.00 | AVG Volume (30 days): | 564.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.97 | EPS Growth: | -7.27 |
| 52 Week Low/High: | $9.83 - $19.00 | Next Earning Date: | 04-13-2026 |
| Revenue: | $50,000,000 | Revenue Growth: | 495.66% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 108.37% |
| P/E Ratio: | -5.31 | Index: | N/A |
| Free Cash Flow: | -153341000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of KalVista Pharmaceuticals Inc. (KALV)
CHIEF EXECUTIVE OFFICER
Avg Cost/Share
$15.57
Shares
10,034
Total Value
$156,197.27
Owned After
442,883
SEC Form 4
CHIEF DEVELOPMENT OFFICER
Avg Cost/Share
$15.57
Shares
4,347
Total Value
$67,668.88
Owned After
226,701
SEC Form 4
CHIEF MEDICAL OFFICER
Avg Cost/Share
$15.57
Shares
5,354
Total Value
$83,344.65
Owned After
138,983
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$15.57
Shares
1,767
Total Value
$27,506.54
Owned After
13,762
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$15.57
Shares
3,975
Total Value
$61,878.03
Owned After
47,003
SEC Form 4
CHIEF EXECUTIVE OFFICER
Avg Cost/Share
$15.00
Shares
1,038
Total Value
$15,570.00
Owned After
442,883
SEC Form 4
CHIEF DEVELOPMENT OFFICER
Avg Cost/Share
$15.00
Shares
1,109
Total Value
$16,635.00
Owned After
226,701
SEC Form 4
CHIEF MEDICAL OFFICER
Avg Cost/Share
$15.00
Shares
1,163
Total Value
$17,445.00
Owned After
138,983
SEC Form 4
CHIEF EXECUTIVE OFFICER
Avg Cost/Share
$15.70
Shares
3,354
Total Value
$52,657.80
Owned After
442,883
SEC Form 4
CHIEF EXECUTIVE OFFICER
Avg Cost/Share
$16.51
Shares
7,294
Total Value
$120,423.94
Owned After
442,883
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Feb 23, 2026 | Sell | $15.57 | 10,034 | $156,197.27 | 442,883 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | Feb 23, 2026 | Sell | $15.57 | 4,347 | $67,668.88 | 226,701 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | Feb 23, 2026 | Sell | $15.57 | 5,354 | $83,344.65 | 138,983 | |
| Piekos Brian | KALV | Chief Financial Officer | Feb 23, 2026 | Sell | $15.57 | 1,767 | $27,506.54 | 13,762 | |
| Sweeny Nicole | KALV | Chief Commercial Officer | Feb 23, 2026 | Sell | $15.57 | 3,975 | $61,878.03 | 47,003 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Feb 18, 2026 | Sell | $15.00 | 1,038 | $15,570.00 | 442,883 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | Feb 18, 2026 | Sell | $15.00 | 1,109 | $16,635.00 | 226,701 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | Feb 18, 2026 | Sell | $15.00 | 1,163 | $17,445.00 | 138,983 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Feb 12, 2026 | Sell | $15.70 | 3,354 | $52,657.80 | 442,883 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Dec 8, 2025 | Sell | $16.51 | 7,294 | $120,423.94 | 442,883 |
Compare KALV vs Leading Stocks
See how KALV stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "KALV KalVista Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.